viernes, 28 de enero de 2022

Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19 | National Institutes of Health (NIH)

Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19 | National Institutes of Health (NIH)

No hay comentarios:

Publicar un comentario